Same‐day molecular testing for targetable mutations in solid tumor cytopathology—The next frontier of the rapid on‐site evaluation

Cancer Cytopathology, Год журнала: 2025, Номер 133(1)

Опубликована: Янв. 1, 2025

Abstract Introduction This study aimed to assess the feasibility of implementing Idylla system, an ultra‐rapid, cartridge‐based assay, as extension rapid on‐site evaluation (ROSE) in cytology. The authors conducted a pilot validation on specimens from non–small cell lung carcinoma, thyroid and melanoma, evaluating four assays designed detect alterations KRAS , EGFR BRAF gene fusions, expression imbalances ALK ROS1 RET NTRK 1/2/3, MET exon 14 skipping transcripts. They investigated providing accurate biomarker molecular testing results cytopathology laboratory within hours specimen collection. Methods evaluated performance characteristics turn‐around‐time system by total 144 cartridge across various types, including fine‐needle aspirate smears, formalin‐fixed paraffin‐embedded (FFPE) blocks, small tissue biopsy FFPE control line scrolls. Results average time input output was 2–3 hours. Accuracy types was: assay: 100%, 94%, GeneFusion 94%. Analytical sensitivity ranged 1% 5% variant allele frequency for all assays. Inter‐assay precision analytical specificity were both 100%. Conclusion Using actionable genetic can be reliably detected cytology samples with minimal requirements. findings this demonstrate incorporating same‐day part ROSE procedures laboratory, ultimately shortening procedure personalized treatment cancer patients.

Язык: Английский

---

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review

Future Oncology, Год журнала: 2024, Номер unknown, С. 1 - 13

Опубликована: Сен. 24, 2024

Next-generation sequencing (NGS) of solid tumors can inform treatment decisions; however, uptake remains low. This objective this systematic review was to identify barriers and facilitators NGS in US oncology settings.

Язык: Английский

---

Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System

Current Oncology, Год журнала: 2025, Номер 32(2), С. 80 - 80

Опубликована: Янв. 31, 2025

Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making a public healthcare system is unknown. Here, BTC patients prospectively received WGTS to inform clinical care at large Canadian academic center. We characterized proportion targetable alterations, treatment recommendations generated by tumor board, therapies received, patient outcomes, financing these treatments. A total 55 underwent care. Of those 55, 28 (51%, 95% CI 38–64%) harbored alterations. Molecular boards recommended consideration for 43 (78% CI: 66–87%) cases. Among 15 who progressed second-line therapy 8 nine No were funded through system, most compassionate access programs from companies. These results highlight challenges potential inequities when implementing precision oncology publicly system.

Язык: Английский

---

Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada

Current Oncology, Год журнала: 2025, Номер 32(3), С. 141 - 141

Опубликована: Фев. 27, 2025

The explosion in biomarker testing over the past two decades continues to transform cancer care Canada and around world. Precision medicine is supported by identifying actionable mutations that direct therapeutic choices, thus improving survival quality of life, especially for patients with advanced/metastatic disease. In addition, our growing understanding genetic basis advanced research employing ever-expanding databases mutations, therapies outcomes. Despite this promising progress, however, access remains inequitable across Canada, detriment patients. Several underlying factors contribute situation, including need investment standardization laboratory infrastructure processes, lack suitable methods cost/benefit evaluations inform funding decisions. 2024, a Canadian conference brought together patients, clinicians, researchers, policy-makers scientists address “Equitable Access Advanced Biomarker Testing Metastatic Cancer Patients”. Two major themes arose from conference: urgent adopt comprehensive genomic profiling (CGP) as standard emerging role liquid biopsy accelerating cancer.

Язык: Английский

---

Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging Applications

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3123 - 3123

Опубликована: Март 28, 2025

Multigene sequencing technologies provide a foundation for targeted therapy and precision oncology by identifying actionable alterations enabling the development of treatments that substantially improve clinical outcomes. This review emphasizes importance having molecular compass guiding treatment decision-making through multitude genetic mutations, showcasing why NGS plays pivotal role in modern oncology.

Язык: Английский

---

The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review

Applied Health Economics and Health Policy, Год журнала: 2025, Номер unknown

Опубликована: Март 29, 2025

Genomic medicine offers an unprecedented opportunity to improve cancer outcomes through prevention, early detection and precision therapy. Health policy makers worldwide are developing strategies embed genomic in routine care. Successful translation of medicine, however, remains slow. This systematic review aims identify synthesise published evidence on the cost effectiveness control. The insights could support efforts accelerate access cost-effective applications human genomics. study protocol was registered with PROSPERO (CRD42024480842), conducted line Preferred Reporting Items for Systematic Reviews Meta Analyses (PRISMA) Guidelines. search run four databases: MEDLINE, Embase, CINAHL EconLit. Full economic evaluations technologies at any stage care, after 2018 English, were included data extraction. identified 137 articles that met inclusion criteria. Most focused prevention (n = 44; 32%), treatment 36; 26%), managing relapsed, refractory or progressive disease 51, 37%). Convergent cost-effectiveness breast ovarian cancer, colorectal endometrial cancers. For treatment, use testing guiding therapy highly likely be effective blood Studies reported advanced metastatic non-small cell lung cancer. There insufficient mixed regarding management other mapped out across care continuum. Gaps literature mean potentially uses control, example rare cancers unknown primary, may being overlooked. Evidence value information budget impact critical, advancements methods include distributional effects, system capacity consumer preferences will valuable. Expanding current base is essential enable sustainable equitable medicine.

Язык: Английский

---

Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting

Cancers, Год журнала: 2025, Номер 17(7), С. 1246 - 1246

Опубликована: Апрель 7, 2025

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality in United States, with poor overall survival across all stages. Less than 20% patients are eligible for curative surgical resection at diagnosis, and despite adjuvant chemotherapy, most will experience disease recurrence within two years. The incorporation immune-based strategies setting remains an area intense investigation unrealized promise. It offers potential providing durable control micro-metastatic following intent surgery enabling personalized treatments based on mutational neoantigen profiles derived from resected specimens. However, these attempts have failed to demonstrate significant clinical success, likely due immunosuppressive tumor microenvironment (TME) individual genetic heterogeneity. Despite challenges, strategies, such as therapeutic vaccines targeted towards neoantigens, demonstrated promise via immune activation induction T-cell infiltration. In this review, we highlight foundational lessons learned previous trials immunotherapy, discussing knowledge gained analyses disappointing results. addition, discuss how data been incorporated design new agents study concepts that proving be exciting more recent trials, shared antigen combination therapy immune-checkpoint inhibitors chemotherapy. This review evaluate novel approaches ongoing future studies provide insight into might evolve address unique challenges treatment PDAC setting.

Язык: Английский

---

DNA-sequencing method maps subsurface fluid flow paths for enhanced monitoring

Communications Earth & Environment, Год журнала: 2025, Номер 6(1)

Опубликована: Апрель 20, 2025

Язык: Английский

---

Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?

The American Journal of Managed Care, Год журнала: 2024, Номер unknown, С. SP550 - SP551

Опубликована: Июнь 1, 2024

THE PAST FEW YEARS have seen major innovation and progress in the oncology landscape with advent of chimeric antigen receptor (CAR) T-cell bispecific engager (BiTE) therapies.These been approved exclusively for treatment hematologic malignancies, less data solid tumors.There are several clinical scenarios, especially within multiple myeloma (MM) space, where overlapping indications exist between CAR T BiTE therapies.With advantages to therapies FDA Oncologic Drugs Advisory Committee (ODAC) looking more closely at

Язык: Английский

---

Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey

Future Oncology, Год журнала: 2024, Номер unknown, С. 1 - 9

Опубликована: Ноя. 28, 2024

The purpose of this study was to identify barriers physicians' NGS use and preferred strategies alleviate these barriers.

Язык: Английский

---